In vitro assessment of cytochrome P450 2C19 potential of Naoxintong

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Chen, Hui ^a,b   Zhang, Ya ^b   Wu, Xiaoying ^a   Li, Candong ^b   Wang, Huan ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYMEPHENYTOIN; CYTOCHROME P450 2C19; HERBACEOUS AGENT; MEPHENYTOIN; NAOXINTONG; PHENACETIN; PHENYTOIN; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROXYLATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; ULTRACENTRIFUGATION;

EID: 84863264701     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/430262     Document Type: Article

References (25)

1. Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation New England Journal of Medicine 2001 345 7 494 502 (Pubitemid 32758501)
2. Gurbel P. A., Bliden K. P., Hiatt B. L., O'Connor C. M., Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 2003 107 23 2908 2913 (Pubitemid 36736631)
3. Bliden K. P., DiChiara J., Tantry U. S., Bassi A. K., Chaganti S. K., Gurbel P. A., Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? Journal of the American College of Cardiology 2007 49 6 657 666 (Pubitemid 46205039)
4. Holmes Jr. D. R., Dehmer G. J., Kaul S., Leifer D., O'Gara P. T., Stein C. M., ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American college of cardiology foundation task force on clinical expert consensus documents and the American Heart Association Journal of the American College of Cardiology 2010 56 4 321 341
5. Mega J. L., Close S. L., Wiviott S. D., Shen L., Hockett R. D., Brandt J. T., Walker J. R., Antman E. M., Macias W., Braunwald E., Sabatine M. S., Cytochrome P-450 polymorphisms and response to clopidogrel New England Journal of Medicine 2009 360 4 354 362
6. Shuldiner A. R., O'Connell J. R., Bliden K. P., Gandhi A., Ryan K., Horenstein R. B., Damcott C. M., Pakyz R., Tantry U. S., Gibson Q., Pollin T. I., Post W., Parsa A., Mitchell B. D., Faraday N., Herzog W., Gurbel P. A., Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy Journal of the American Medical Association 2009 302 8 849 858
7. Lau W. C., Gurbel P. A., Watkins P. B., Neer C. J., Hopp A. S., Carville D. G. M., Guyer K. E., Tait A. R., Bates E. R., Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 2004 109 2 166 171 (Pubitemid 38114134)
8. Chen H., Yu G., Sun H., Wu X., Wang H., Comparison of adjunctive naoxintong versus clopidogrel in volunteers with the CYP2C192 gene mutation accompanied with qi deficiency and blood stasis constitution Evidence-Based Complementary and Alternative Medicine 2011 2011 10
9. Von Bahr C., Groth C. G., Jansson H., Drug metabolism in human liver in vitro: establishment of a human liver bank Clinical Pharmacology and Therapeutics 1980 27 6 711 725 (Pubitemid 10072956)
10. Omura T., Sato R., The carbon monoxide-binding pigment of liver microsomes. l. Evidence for its hemoprotein nature The Journal of biological chemistry 1964 239 2370 2378
11. Chiba K., Manabe K., Kobayashi K., Takayama Y., Tani M., Ishizaki T., Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes European Journal of Clinical Pharmacology 1993 44 6 559 562 (Pubitemid 23197842)
12. Sibbing D., Morath T., Stegherr J., Braun S., Vogt W., Hadamitzky M., Schmig A., Kastrati A., Von Beckerath N., Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thrombosis and Haemostasis 2009 101 4 714 719
13. Gilard M., Arnaud B., Cornily J. C., Le Gal G., Lacut K., Le Calvez G., Mansourati J., Mottier D., Abgrall J. F., Boschat J., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study Journal of the American College of Cardiology 2008 51 3 256 260
14. Lau W. C., Gurbel P. A., The drug-drug interaction between proton pump inhibitors and clopidogrel CMAJ 2009 180 7 699 700
15. Charlot M., Ahlehoff O., Norgaard M. L., Jrgensen C. H., Srensen R., Abildstrm S. Z., Hansen P. R., Madsen J. K., Kber L., Torp-Pedersen C., Gislason G., Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study Annals of Internal Medicine 2010 153 6 378 386
16. Hellum B. H., Hu Z., Nilsen O. G., The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes Basic and Clinical Pharmacology and Toxicology 2007 100 1 23 30 (Pubitemid 46051439)
17. Fan L., Wang G., Wang L. S., Chen Y., Zhang W., Huang Y. F., Huang R. X., Hu D. L., Wang D., Zhou H. H., Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole Acta Pharmacologica Sinica 2007 28 10 1685 1692 (Pubitemid 47493278)
18. Wang L. S., Zhou G., Zhu B., Wu J., Wang J. G., Abd El-Aty A. M., Li T., Liu J., Yang T. L., Wang D., Zhong X. Y., Zhou H. H., St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole Clinical Pharmacology and Therapeutics 2004 75 3 191 197 (Pubitemid 38314868)
19. Yin O. Q. P., Tomlinson B., Waye M. M. Y., Chow A. H. L., Chow M. S. S., Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole Pharmacogenetics 2004 14 12 841 850 (Pubitemid 40054339)
20. Lau W. C., Gurbel P., Bates E. R., St. Johns Wort enhances the platelet inhibitory effect of clopidogrel in clopidogrel resistant healthy volunteers Journal of the American College of Cardiology 2005 45 supplement A, abstract 382A
21. Lau W. C., Welch T. D., Shields T., Rubenfire M., Tantry U. S., Gurbel P. A., The effect of St. John's wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: Increased platelet inhibition by enhancement of CYP 3A4 metabolic activity Journal of Cardiovascular Pharmacology 2011 57 1 86 93
22. Chen C., Venketasubramanian N., Gan R. N., Lambert C., Picard D., Chan B. P. L., Chan E., Bousser M. G., Xuemin S., Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery Stroke 2009 40 3 859 863
23. Chen D. K., Zhang H. Q., Zhang J. H., Intervening effect of naoxintong on anti-platelet treatment with aspirin Chinese Journal of Integrated Traditional and Western Medicine 2008 28 9 843 846
24. Huang M.-W., Wang H., Zhong W.-J., Wu X.-Y., Chen H., Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi Journal of Chinese Integrative Medicine 2011 9 1 38 48
25. Wang H., Zhong W. J., Huang M. W., Efficacy of dual antiplatelet therapy combined with Buchang Naoxintong Capsules following coronary microembolization induced by homologous microthrombi in rats Chinese Journal of Integrative Medicine 2011 17 12 917 924